About 2,643 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  955 results

Current status and future prospects of nanomedicine for arsenic trioxide delivery to so...
Medicinal Research Reviews; Sönksen M, Kerl K et. al.

Jul 27th, 2021 - Despite having a rich history as a poison, arsenic and its compounds have also gained a great reputation as promising anticancer drugs. As a pioneer, arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia. Many in vit...

RBCK1-TRIB3 decelerated the progression of acute promyelocytic leukemia.
Hematological Oncology; Zhang X, Yu W

Jul 27th, 2021 - Under the differentiation induction therapy with all-trans retinoic acid and arsenic trioxide, nearly 95% of typical acute promyelocyte leukemia (APL), which is characterized by the presence of PML-RARA, patients can be cured. Though its good prog...

Evaluation of pretreatment telomere length as a prognostic marker in intermediate-risk ...
International Journal of Laboratory Hematology; Gu R, Cao J et. al.

Jul 22nd, 2021 - The current framework for risk stratification is still insufficient for highly heterogeneous intermediate-risk acute myeloid leukemia (IRC-AML), which lacks specific genomic abnormalities. In order to incorporate novel biomarkers to refine current...

Variant Acute Promyelocytic Leukemia Presenting Without Auer Rods Highlights the Need f...
Laboratory Medicine; Courville EL, Shantzer L et. al.

Jul 17th, 2021 - Variant acute promyelocytic leukemia (vAPL) is a rare leukemia characterized by rearrangement between RARα and a non-PML partner gene. This type of leukemia can be difficult to recognize by histomorphologic evaluation, particularly in patients wit...

see more →

Guidelines  1 results

Acute myeloid leukemia, version 2.2013.
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  37 results

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Feb 6th, 2020 - Objectives: To perform quantitative PCR using known leukemia specific markers in diagnostic bone marrow specimens of patients with newly diagnosed APL and ALL and to correlative pre-treatment copy number with other biologic and molecular features,...

Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

Nov 21st, 2018 - PRIMARY OBJECTIVES: I. To evaluate if the proposed patient care strategy, that includes use of simplified guidelines along with acute promyelocytic leukemia (APL) expert support, decreases the one-month induction mortality rate from 30% to under 1...

Phase III Trial in Acute Promyelocytic Leukemia Patients

Oct 22nd, 2018 - Arm I: Induction therapy: Patients receive oral tretinoin twice daily and arsenic trioxide IV over 2 hours on days 1-60. Patients achieving hematological complete remission go on to receive consolidation therapy. Consolidation therapy: Patients re...

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Oct 1st, 2018 - This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic...

Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin

Aug 6th, 2018 - Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if the combination of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuz...

see more →

News  54 results

How to Treat Differentiation Syndrome in APL and AML

Sep 18th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says

Jul 17th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy

Aug 30th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →